Literature DB >> 12529668

FLT3 mutations in acute myeloid leukemia cell lines.

H Quentmeier1, J Reinhardt, M Zaborski, H G Drexler.   

Abstract

Internal tandem duplications (ITD) and D835 point mutations of the receptor tyrosine kinase (RTK) FLT3 are found in a high proportion of cases with acute myeloid leukemia (AML). These genetic aberrations may lead to the constitutive activation of the receptor, thus providing the molecular basis for a persisting growth stimulus. We have screened 69 AML-derived cell lines for FLT3 mutations. Four of these cell lines showed ITD of the FLT3 gene, none carried a D835 point mutation. Two cell lines (MUTZ-11 and MV4-11) expressed exclusively the mutated allele, the other two cell lines (MOLM-13 and PL-21) displayed a mutated and the wild-type version of the gene. Although mutationally activated FLT3 is supposed to substitute for the stimulatory signal of a growth factor, one of these cell lines (MUTZ-11) was strictly cytokine-dependent. FLT3 transcripts were found in all four cell lines, but the constitutively phosphorylated receptor protein was clearly detectable only in cell line MV4-11, possibly explaining why MUTZ-11 cells were growth-factor dependent. Thus, not all FLT3 ITD-positive cells express high levels of the active receptor protein, a finding that might be of relevance for a possible future application of a kinase inhibitor as therapeutic agent. It had been described that STAT-5 phosphorylation was part of the FLT3 signalling chain and that STAT-5 molecules were constitutively phosphorylated in FLT3 ITD-positive cells. Although we observed the constitutive phosphorylation of STAT-5 molecules in FLT3-mutant cells, FLT3 ligand (FL) did not induce STAT-5 phosphorylation in FLT3 wild-type cells. These results suggest that the signalling mechanisms of the mutated FL receptor differ at least to some extent from those conferred by wild-type FLT3. In conclusion, (1) not all cells with FLT3 ITD express significant amounts of the mutated receptor protein; (2) signals downstream from wild-type and mutant FLT3 receptors are not 100% identical; and (3) MV4-11 represents a model cell line for FLT3 ITD signalling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12529668     DOI: 10.1038/sj.leu.2402740

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  101 in total

1.  A novel class of small molecule inhibitors of HDAC6.

Authors:  Elizabeth S Inks; Benjamin J Josey; Sean R Jesinkey; C James Chou
Journal:  ACS Chem Biol       Date:  2011-11-11       Impact factor: 5.100

2.  Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Authors:  Xiaoyang Li; Yuqi Jiang; Yuri K Peterson; Tongqiang Xu; Richard A Himes; Xin Luo; Guilin Yin; Elizabeth S Inks; Nathan Dolloff; Stephanie Halene; Sherine S L Chan; C James Chou
Journal:  J Med Chem       Date:  2020-05-06       Impact factor: 7.446

3.  Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication.

Authors:  Akihiro Abe; Hitoshi Kiyoi; Manabu Ninomiya; Tomio Yamazaki; Takuhei Murase; Kazutaka Ozeki; Momoko Suzuki; Fumihiko Hayakawa; Akira Katsumi; Nobuhiko Emi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

4.  An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.

Authors:  Yik Andy Yeung; Veena Krishnamoorthy; Danielle Dettling; Cesar Sommer; Kris Poulsen; Irene Ni; Amber Pham; Wei Chen; Sindy Liao-Chan; Kevin Lindquist; S Michael Chin; Allison Given Chunyk; Wenyue Hu; Barbra Sasu; Javier Chaparro-Riggers; Ivana Djuretic
Journal:  Mol Ther       Date:  2020-01-14       Impact factor: 11.454

5.  Antileukemic activity of Tillandsia recurvata and some of its cycloartanes.

Authors:  Henry I C Lowe; Ngeh J Toyang; Charah T Watson; Kenneth N N Ayeah; Joseph Bryant
Journal:  Anticancer Res       Date:  2014-07       Impact factor: 2.480

6.  Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.

Authors:  Jesse J McClure; Cheng Zhang; Elizabeth S Inks; Yuri K Peterson; Jiaying Li; C James Chou
Journal:  J Med Chem       Date:  2016-10-26       Impact factor: 7.446

7.  The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

Authors:  Yun Dai; Shuang Chen; Maciej Kmieciak; Liang Zhou; Hui Lin; Xin-Yan Pei; Steven Grant
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

8.  Efficient production of bioactive recombinant human Flt3 ligand in E. coli.

Authors:  Kenneth Verstraete; Sina Koch; Sevgi Ertugrul; Isabel Vandenberghe; Maarten Aerts; Gonzalez Vandriessche; Christian Thiede; Savvas N Savvides
Journal:  Protein J       Date:  2009-02       Impact factor: 2.371

9.  Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.

Authors:  Andreas Schirmer; Jonathan Kennedy; Sumati Murli; Ralph Reid; Daniel V Santi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

10.  Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines.

Authors:  Therese Bredholt; Elizabeth Ao Dimba; Hanne R Hagland; Line Wergeland; Jørn Skavland; Kjell O Fossan; Karl J Tronstad; Anne C Johannessen; Olav K Vintermyr; Bjørn T Gjertsen
Journal:  Mol Cancer       Date:  2009-11-13       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.